Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | Director | June 13, 2018 | June 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celldex Therapeutics, Inc.
Report date June 13, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2028-06-13 | Direct | 67,000 |
Reported balance
After 2018-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-13 · Grant · Acquired 67,000 · Balance 67,000 F1: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2018 Filed Jun 15, 2018 11:27 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001179110-18-008558 · edgar.xml · derivative · entry 1 ELLBERGER LARRY · CIK 0001219551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2028-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:29 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001179110-17-009163 · edgar.xml · derivative · entry 2 ELLBERGER LARRY · CIK 0001219551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-15 F2 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. F3 · derivative.exercise_date: Such option vests in three equal annual installments beginning June 15, 2018. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 13:29 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantCommon Stock, par value $0.001 per share | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-009163 · edgar.xml · nonDerivative · entry 1 ELLBERGER LARRY · CIK 0001219551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,500 F1 · price: On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.